AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Melexis N.V.

Earnings Release Apr 1, 2020

3975_iss_2020-04-01_c24cc1e7-dedd-43c6-940b-de1b55bec78e.pdf

Earnings Release

Open in Viewer

Opens in native device viewer

Press release - Regulated Information

Melexis expects Q1 2020 sales at high end of guidance, withdraws full year guidance and reduces dividend

Intermediate declaration by the Board of Directors

Ieper, Belgium – April 1st, 2020, 18.00 hrs CET

Melexis announces today that it expects its first quarter 2020 sales to be around the level of 138 million EUR, at the high end of the 134-138 million EUR guidance provided in the beginning of the year.

Despite this solid start of the year, Melexis has decided to withdraw its full year 2020 outlook as the economic impact resulting from the COVID-19 pandemic cannot be quantified at this moment.

As a matter of prudence and in light of the extreme unpredictability of the current situation, the Board of Directors has decided to propose to the annual shareholders' meeting to pay out over the result of 2019 a total dividend of 1.30 EUR gross per share, which was paid in October 2019 as interim dividend, meaning a final dividend would not be paid.

Melexis has a strong balance sheet. At the end of the first quarter, Melexis cash position amounted to around 50 million EUR and the outstanding bank debt to 62 million EUR. Unused committed credit lines equal 112 million EUR.

Françoise Chombar, CEO, comments:

"We live and operate in unprecedented times, as COVID-19 continues to spread globally, impacting everyday life and work of our people, customers and suppliers. Melexis continues to closely monitor the situation. Supply chain and business contingency planning ensures that our manufacturing sites keep running under the best achievable circumstances. Part of Melexis products like temperature sensors are critical components to many of the equipment to overcome the pandemic, ranging from diagnostics, over fever measurement and respiratory devices. Likewise, we continue to serve our automotive customers in the best possible way."

Melexis will publish its first quarter 2020 full results on April 29th, 2020 at 7 hrs CET.

For further information: Investor Relations - Phone: +32 13 67 07 79 - Email: [email protected]

About Melexis

Combining a passion for technology with truly inspired engineering, Melexis designs, develops and delivers innovative micro-electronic solutions that enable designers to turn ideas into applications that support the best imaginable future. The company's advanced mixed-signal semiconductor sensor and actuator components address the challenges of integrating sensing, driving and communication into next-generation products and systems that improve safety, raise efficiency, support sustainability and enhance comfort. Melexis is headquartered in Belgium and employs over 1500 people in 19 locations worldwide. The company is publicly traded on Euronext Brussels (MELE). For more information, visit www.melexis.com

Disclaimer

Except for those statements that report the Company's historical results, the statements being made are forward looking statements. Actual results could differ materially from those projected in the forwardlooking statements. Factors which could cause actual results to differ from expectations include the following: volatility in supply and demand affecting revenues and market prices, price and availability of silicon foundry, assembly and test prices, assembly and test subcontract capacity required to meet financial targets and/or meet backlog requirements, risks and delays associated with bringing up new production capabilities or with deliveries from subcontractors, timing and market acceptance of new products, increased expenses associated with new product acceptance of new products, increased expenses associated with new product introductions of process changes, delays in developing or achieving volume production of new products, which can result in delays or failure to contribute to revenues and profits, ability of the Company to maintain its customer and vendor base and delays in and/or inability in raising additional capital.

Talk to a Data Expert

Have a question? We'll get back to you promptly.